The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use
Open accessAbstract
OBJECTIVE: To evaluate the effects of metreleptin in distinct subgroups of patients with generalized lipodystrophy (GL) and partial lipodystrophy (PL), using multivariate linear regression modeling to account for the role of patients' baseline usage of concomitant glucose and lipid-lowering medications and other covariates on their outcomes. MATERIALS AND METHODS: statistical analysis of two published single-arm, interventional, phase 2 clinical trials at NIH was conducted. Concomitant medication use was assessed for the clinical trial population using prescription fill data, measured at baseline and the post-one year following metreleptin initiation. Pre-specified co-primary efficacy endpoints measured were change from baseline in HbA1c at month 12, and the percent change from baseline in fasting serum triglycerides (TG) at month 12. Descriptive and statistical analyses were conducted for the overall population, the separate populations with GL and PL, and additional PL subgroups defined by baseline metabolic markers of elevated HbA1c and elevated fasting TG. RESULTS: As previously reported, improvement in HbA1c and fasting TG from baseline to 12 months on metreleptin were observed in the overall population (mean change -1.57 percentage points and median change -37.9%, respectively) and subgroups. For both HbA1c and TG, baseline levels were significant predictors of changes after metreleptin. After considering baseline characteristics such as disease type, age, sex, and baseline HbA1c, baseline insulin use was not found to be a significant predictor of HbA1c improvement following metreleptin initiation. Similar results were seen for TG levels, with the use of any lipid-lowering medications at baseline not found to be a significant predictor of reductions in fasting TG levels. CONCLUSIONS: Patients treated with metreleptin experienced statistically significant improvement in metabolic markers of glycemic and hypertriglyceridemic control-e.g. HbA1c and triglyceride levels-across various subgroups after controlling for baseline characteristics and concomitant medication usage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The appetite-suppressing effect of leptin analogs rapidly diminishes with the development of leptin resistance; thus, the use of metreleptin is limited to cases of congenital or acquired leptin deficiency [122].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [122]
In the citing paper
“The anorexigenic effect of leptin analogues is quickly diminished by the development of leptin resistance such that use of metreleptin is limited to replacement therapy for individuals with congenital or acquired leptin deficiency [46].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [46]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Acquired and Inherited Lipodystrophies
Garg, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra025261 · Cited by 941
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araujo-Vilar, D., Cheung, P. T., Dunger, D., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 529
Self-citationIntroduction to multivariate regression analysis.
Alexopoulos, E. C. (2010) · Europe PMC (PubMed Central) · Cited by 366
Lipodystrophy: metabolic insights from a rare disorder
Huang-Doran, I., Sleigh, A., Rochford, J. J., O'Rahilly, S., & Savage, D. B. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0272 · Cited by 215
Diker-Cohen, T., Cochran, E., Gorden, P., & Brown, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4491 · Cited by 178
Self-citationBrown, R. J., Oral, E. A., Cochran, E. K., Araújo‐Vilar, D., Savage, D. B., Long, A., Fine, G., Salinardi, T. C., & Görden, P. (2018) · Endocrine · doi:10.1007/s12020-018-1589-1 · Cited by 146
Self-citationMcDuffie, J. R., Riggs, P. A., Calis, K. A., Freedman, R. J., Oral, E. A., DePaoli, A. M., & Yanovski, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031868 · Cited by 129
Research works printed but not linked: 2
- Myalept (metreleptin) for injection for subcutaneous use [prescribing information] Cambridge, MA: Aegerion Pharmaceuticals Inc. 2020. [updated May; cited 2020 July 6]. Available from: http://www.myalept.com/prescribing-information
- Alexopoulos EC., 2010, Hippokratia, 14, 23
Cited by
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“The appetite-suppressing effect of leptin analogs rapidly diminishes with the development of leptin resistance; thus, the use of metreleptin is limited to cases of congenital or acquired leptin deficiency [122].”
BackgroundRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
Metadata
- Authors
- Adamski, K., Cook, K., Gupta, D., Morris, E., Tuttle, E., Carr, E., Cremasco, F., Cochran, E., & Brown, R. J.
- Affiliations
- Analysis Group (United States) (US)
- Amryt Pharmaceuticals DAC, Dublin, Ireland
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Corresponding author
- Cook, Keziah
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2021-09-26
- Volume
- 37
- Issue
- 11
- Pages
- 1881-1889
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W3198114250
- Cited by
- 11
- References
- 17
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 3
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amryt Pharmaceuticals and Aegerion Pharmaceuticals
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- metreleptin, lipodystrophy, generalized lipodystrophy, partial lipodystrophy, HbA1c, glucose-lowering medications, lipid-lowering drugs, insulin use, predictors of treatment response, hypertriglyceridemia, glycemic control
- MeSH terms
- Blood Glucose, Fasting, Humans, Lipodystrophy, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. https://app.cochat.ai/papers/10.1080/03007995.2021.1976125
- The paper
- Adamski, K., Cook, K., Gupta, D., Morris, E., Tuttle, E., Carr, E., Cremasco, F., Cochran, E., & Brown, R. J. (2021). Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2021.1976125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.